Scholarlink

Background <p>Brain metastases (BMs) are common in patients with non-small-cell lung cancer (NSCLC) and remain a major therapeutic challenge. While immune checkpoint inhibitors (ICIs) have improved systemic outcomes, their intracranial efficacy and prognostic determinants in patients with BMs, particularly in comparison with chemotherapy, remains insufficiently characterized.</p> Methods <p>We conducted a multicenter, retrospective cohort study including NSCLC patients with BMs who received ICIs or chemotherapy alone. Propensity score matching was performed to balance baseline characteristics between treatment groups. Intracranial and extracranial responses, intracranial progression-free survival (iPFS), extracranial PFS (ePFS), and overall survival (OS) were compared. Logistic regression and Cox proportional hazards models were used to identify prognostic factors associated with treatment response and survival.</p> Results <p>In the matched cohort, patients treated with immunotherapy achieved significantly longer median OS than those receiving chemotherapy (18.9 vs. 13.3 months, <i>p</i> = 0.001), while intracranial and extracranial PFS were not significantly prolonged (median iPFS: 10.4 vs. 9.6 months, <i>p</i> = 0.09; median ePFS: 7.8 vs. 7.1 months, <i>p</i> = 0.06). In the intracranial efficacy–evaluable cohort, the intracranial objective response rate (iORR) was 38.9% vs. 35.2% (<i>p</i> = 0.759), whereas the extracranial objective response rate (eORR) was 45.9% vs. 18.0% (<i>p</i> = 0.006), favoring immunotherapy. Concordance between intracranial and extracranial responses was about 70% across groups. In the immunotherapy cohort, development of immune-related adverse events (irAEs), receipt of stereotactic radiotherapy (SRT), and prior radiotherapy were associated with improved OS. Patients receiving intracranial radiotherapy before ICIs achieved a median OS of 32.3 months versus 19.0 months with concurrent therapy. In the chemotherapy cohort, age ≥ 65 years and multiple brain metastases were associated with inferior survival.</p> Conclusions <p>This real-world study suggests that immunotherapy may confer a survival advantage over chemotherapy in NSCLC patients with brain metastases, with efficacy less dependent on baseline factors such as age or performance status. Radiotherapy administered before ICIs appeared to be associated with favorable outcomes, although this observation remains hypothesis-generating given the study limitations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical outcomes and predictive factors of immunotherapy efficacy in non-small-cell lung cancer brain metastases: a comparative study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月7日

查看全文
  • Yuxi Wei,
  • Rongzhen Li,
  • Xiaoyan Liu,
  • Yuequan Shi,
  • Yan Xu,
  • Jing Zhao,
  • Minjiang Chen,
  • Mengzhao Wang

摘要

Background

Brain metastases (BMs) are common in patients with non-small-cell lung cancer (NSCLC) and remain a major therapeutic challenge. While immune checkpoint inhibitors (ICIs) have improved systemic outcomes, their intracranial efficacy and prognostic determinants in patients with BMs, particularly in comparison with chemotherapy, remains insufficiently characterized.

Methods

We conducted a multicenter, retrospective cohort study including NSCLC patients with BMs who received ICIs or chemotherapy alone. Propensity score matching was performed to balance baseline characteristics between treatment groups. Intracranial and extracranial responses, intracranial progression-free survival (iPFS), extracranial PFS (ePFS), and overall survival (OS) were compared. Logistic regression and Cox proportional hazards models were used to identify prognostic factors associated with treatment response and survival.

Results

In the matched cohort, patients treated with immunotherapy achieved significantly longer median OS than those receiving chemotherapy (18.9 vs. 13.3 months, p = 0.001), while intracranial and extracranial PFS were not significantly prolonged (median iPFS: 10.4 vs. 9.6 months, p = 0.09; median ePFS: 7.8 vs. 7.1 months, p = 0.06). In the intracranial efficacy–evaluable cohort, the intracranial objective response rate (iORR) was 38.9% vs. 35.2% (p = 0.759), whereas the extracranial objective response rate (eORR) was 45.9% vs. 18.0% (p = 0.006), favoring immunotherapy. Concordance between intracranial and extracranial responses was about 70% across groups. In the immunotherapy cohort, development of immune-related adverse events (irAEs), receipt of stereotactic radiotherapy (SRT), and prior radiotherapy were associated with improved OS. Patients receiving intracranial radiotherapy before ICIs achieved a median OS of 32.3 months versus 19.0 months with concurrent therapy. In the chemotherapy cohort, age ≥ 65 years and multiple brain metastases were associated with inferior survival.

Conclusions

This real-world study suggests that immunotherapy may confer a survival advantage over chemotherapy in NSCLC patients with brain metastases, with efficacy less dependent on baseline factors such as age or performance status. Radiotherapy administered before ICIs appeared to be associated with favorable outcomes, although this observation remains hypothesis-generating given the study limitations.